RxDoctor Payments DataLook up a doctor →

Thomas Bender, MD

Dermatology · Mobile, ALNPI 1649266792

Payments from drug & device makers

$243,763in general payments, 2019–2025

Across 1,356 payments — averaging $179.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • LEO Pharma AS$58K
  • AbbVie$51K
  • Dermavant Sciences, Inc.$45K
  • Sun Pharmaceutical Industries Inc.$35K
  • Organon$15K
  • Pfizer$11K
  • plus $29K from 40 others
$10,000in research payments, 2019–2025

Across 1 payment — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sensus Healthcare, Inc.$10K

What the payments were for

  • Consulting fees$2,7902%
  • Speaking & faculty fees$101,67272%
  • Travel & lodging$9,1486%
  • Food & beverage$28,06520%
  • Education$4610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$243,763 in reported general payments places this provider in the 90th percentile of 168 dermatology providers in Alabama.

See all dermatology providers in Alabama

Medicare billing

Part B allowed, 2024
$731,160
Medicare patients
1,134
Services billed
14,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa24$519,393
Dupixent PenDupilumab95$374,024
Cosentyx Sensoready (2 Pens)Secukinumab15$109,282
RinvoqUpadacitinib11$69,328
Ketoconazole750$14,737
Clobetasol Propionate287$13,219
Tacrolimus69$10,806
Azelaic Acid89$9,507
Pimecrolimus36$9,008
Triamcinolone Acetonide455$7,556
Tazarotene13$5,616
Metronidazole118$5,610
Minocycline Hcl139$4,391
Fluocinolone AcetonideFluocinolone/Shower Cap64$4,183
Desonide24$2,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$50,658$69,32811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 168 dermatology providers in Alabama.

Other dermatology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →